4D Molecular Therapeutics (FDMT) Share-based Compensation (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Share-based Compensation data on file, last reported at $4.5 million in Q1 2026.

• On a quarterly basis, Share-based Compensation fell 36.26% year-over-year to $4.5 million in Q1 2026; TTM through Mar 2026 was $19.5 million, a 42.83% decrease from a year earlier, with the FY2025 full-year figure at $34.2 million, down 37.25% from the prior year.
• Share-based Compensation for Q1 2026 stood at $4.5 million, down from $5.6 million in the prior quarter.
• Over the last five years, Share-based Compensation for FDMT reached as high as $14.5 million in Q4 2024 and fell as low as $3.9 million in Q1 2022.
• Historically, Share-based Compensation has averaged $5.7 million across 5 years, with a median of $5.0 million in 2025.
• Across the five-year window, Share-based Compensation surged 722.8% in 2022 and sank 61.78% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $4.3 million in 2022, then surged by 36.06% to $5.9 million in 2023, then soared by 145.71% to $14.5 million in 2024, then sank by 61.78% to $5.6 million in 2025, then retreated by 19.81% to $4.5 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $4.5 million in Q1 2026, $5.6 million in Q4 2025, and $4.5 million in Q3 2025.